Prostate Cancer Clinical Trial
Study of ORIC-101 in Combination With Enzalutamide
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with enzalutamide (XtandiÂ®) when administered to patients with metastatic prostate cancer progressing on enzalutamide.
ORIC-101 is a small molecule GR antagonist being developed for the treatment of patients with solid tumor malignancies. Mechanistically, ORIC-101 inhibits GR transcriptional activity and blocks the pro-survival signals mediated by the activated nuclear receptor.
This is an open-label, single arm, multicenter, dose escalation followed by dose expansion study to assess the safety and preliminary antitumor activity of ORIC-101 in combination with enzalutamide in patients progressing on enzalutamide. Patients deemed eligible will receive treatment with ORIC-101 in addition to continuing their current enzalutamide therapy.
Escalating dose levels of ORIC-101 will be administered orally, once daily in combination with enzalutamide 160 mg. Parallel enrollment for assessment of PK/PD modulation in up to 3 additional patients presenting with tumors expressing high levels of GR (GR-high) may be performed at each dose level after the dose level has cleared the initial dose-limiting toxicity evaluation period; these additional patients may serve as supplemental patients for selection of the maximum tolerated dose and/or RP2D.
Dose expansion will further evaluate the safety and preliminary antitumor activity of ORIC-101 in patients presenting with different levels of GR expressing-tumors.
Histologically or cytologically confirmed adenocarcinoma of the prostate
Metastatic prostate cancer currently being treated with enzalutamide (XtandiÂ®) 160 mg once daily plus surgical or ongoing chemical castration, with baseline testosterone level <50 ng/dL
Must have been on treatment with enzalutamide for at least 3 months prior to documented evidence of PSA progression defined as per PCWG3: minimum of 2 rising values (3 measurements) obtained a minimum of one week apart with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of progression)
Agreement and ability to undergo on-study core biopsies, as follows, through a procedure that is deemed to be clinically feasible and not carry significant risk:
one pre-treatment tumor biopsy obtained while on treatment with enzalutamide prior to enrollment on this study; and
one post-treatment tumor biopsy during Cycle 2
one end of treatment tumor biopsy (optional)
ECOG performance status 0 or 1
Life expectancy of at least 3 months
Adequate organ function as defined by the following criteria:
ANC â‰¥1500 cells/mm3 (1.5 Ã— 103 cells/mm3)
Platelets â‰¥100,000 /ÂµL (100 Ã— 109 /L)
Hemoglobin â‰¥9.0 g/dL (90 g/L)
AST (SGOT) or ALT (SGPT) â‰¤2.5 Ã— ULN, â‰¤5.0 Ã— ULN for patients with liver metastases
Bilirubin â‰¤1.5 Ã— ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible
QTcF â‰¤480 msec
Capable of giving signed informed consent
No intervening therapy between enzalutamide treatment and enrollment on this study
Any other active malignancy, with the exception of adequately treated non-melanoma skin cancer, adequately treated superficial bladder cancer, stage 1 or 2 solid tumor malignancies without evidence of disease, or other solid tumors curatively treated with no evidence of disease for â‰¥5 years from enrollment
Current treatment on another therapeutic clinical trial
Prior or current treatment with ORIC-101 or any other GR antagonist (eg, CORT-125281, mifepristone, relacorilant)
Prior chemotherapy in the metastatic castration-resistant prostate cancer setting
Prior treatment with a second-generation AR modulator (eg, apalutamide, abiraterone, darolutamide)
History of Cushing's syndrome or adrenal insufficiency
History or presence of CNS metastases
History of seizures or condition that may predispose to seizures
Current (at C1D1) or requirement for chronic use of systemic corticosteroids with the exception of inhaled, topical, intraocular, intranasal, or intraarticular corticosteroids
Current (within 10 days prior to first dose of ORIC-101) or expected on-study treatment with specified strong CYP3A4 inhibitors or inducers
Receiving any other anticancer therapy, including radiotherapy within 21 days prior to C1D1. Patients must have recovered from all toxicities from prior anticancer therapies and/or radiotherapy
Major surgery within 21 days prior to C1D1 or incomplete recovery from adverse effects resulting from such procedure
Known human immunodeficiency virus (HIV) infection, unless patient is healthy and has a low risk of AIDS-related outcomes
Active Hepatitis B or C infection
Any other condition or circumstance (eg, clinical, psychological, familial, sociological, inability to swallow oral study drug) that, in the opinion of the investigator, may interfere with protocol compliance or contraindicates participation in the study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
New York New York, 10065, United States
Myrtle Beach South Carolina, 29572, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.